2-(1-methoxyethyl)-3-methyl oxirane | 340184-72-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: 2-(1-methoxyethyl)-3-methyl oxirane
• 英文别名: 2-(1-methoxyethyl)-3-methyloxirane
• CAS: 340184-72-7
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: APBCSPGDOXIPKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲醇 、 2-(1-methoxyethyl)-3-methyl oxirane 在 硫酸 作用下， 生成 2,4-dimethoxy-3-hydroxy pentane
  参考文献：
  名称：

  Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity

  摘要：

  具有高亲和力和特异性的环状多氮螯合剂，当与碱土金属阳离子的络合物一起给药时，表现出生物活性的意外改善，其中以Ca(II)和Mg(II)的络合物最为显著，尤其是Ca(II)。由于这种改善，这些络合物在治疗病理条件，包括缺血和缺血再灌注损伤方面特别有效。

  公开号：

  US20050112066A1
• 作为产物：
  描述：

  2-(1-bromoethyl)-3-methyl oxirane 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 生成 2-(1-methoxyethyl)-3-methyl oxirane
  参考文献：
  名称：

  Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements

  摘要：

  表现出对第一过渡系列元素具有螯合亲和力和选择性的化合物被用于治疗患有缺血、持续性癫痫和创伤等疾病的患者，以提供神经保护、心脏保护或两者兼而有之。这些化合物在被给药时会与可螯合的铁和铜阳离子形成络合物，从而减轻这些阳离子催化哈伯-魏斯反应的能力，这些反应会产生导致组织损伤的有毒羟自由基。这些化合物还会与可螯合的锌阳离子形成络合物，从而抑制与过多可螯合锌相关的细胞毒性。

  公开号：

  US20040006055A1

文献信息

• Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
  申请人：Concat, Ltd.

  公开号：US06264966B1

  公开（公告）日：2001-07-24

  This invention involves the use of a class of compounds with chelation affinity and selectivity for first transition series elements. Application or administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease of the bioavailability and/or chemical action of first transition series elements. These characteristics make such compounds useful in cosmetics and personal care products to decrease odor arising from microbial growth on body surfaces and in body cavities, decrease microbial growth on teeth, plaque, and gums that cause tooth decay and gum disease, inhibition of oxidative damage to the skin, inhibition of enzymatic action of metalloenzymes dependent on first transition series elements, and inhibition of reperfusion injury.

  这项发明涉及一类具有螯合亲和力和选择性的化合物，用于第一过渡系列元素。应用或施用自由或结合的化合物，或自由或结合的化合物的生理盐，会导致第一过渡系列元素的生物利用度和/或化学作用降低。这些特性使得这种化合物在化妆品和个人护理产品中非常有用，可以降低身体表面和体腔微生物生长所产生的气味，减少牙齿、牙菌斑和牙龈上的微生物生长，防止牙齿蛀牙和牙龈疾病，抑制皮肤氧化损伤，抑制依赖第一过渡系列元素的金属酶的酶促作用，以及抑制再灌注损伤。
• Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
  申请人：——

  公开号：US20010041170A1

  公开（公告）日：2001-11-15

  This invention involves the use of a class of compounds with chelation affinity and selectivity for first transition series elements. Application or administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease of the bioavailability and/or chemical action of first transition series elements. These characteristics make such compounds useful in cosmetics and personal care products to decrease odor arising from microbial growth on body surfaces and in body cavities, decrease microbial growth on teeth, plaque, and gums that cause tooth decay and gum disease, inhibition of oxidative damage to the skin, inhibition of enzymatic action of metalloenzymes dependent on first transition series elements, and inhibition of reperfusion injury.

  这项发明涉及使用一类对第一过渡系列元素具有螯合亲和力和选择性的化合物。应用或给予自由或结合化合物，或自由或结合化合物的生理盐，可导致第一过渡系列元素的生物利用度和/或化学作用降低。这些特性使得这些化合物在化妆品和个人护理产品中非常有用，可减少身体表面和身体腔内微生物生长引起的气味，减少导致牙齿蛀牙和牙龈疾病的牙菌斑和牙龈微生物生长，抑制皮肤氧化损伤，抑制依赖于第一过渡系列元素的金属酶的酶促作用，以及抑制再灌注损伤。
• Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
  申请人：Chelator LLC

  公开号：US06583182B1

  公开（公告）日：2003-06-24

  This invention involves synthesis and use of a class of compounds with chelation affinity and selectivity for first transition series elements. Administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease in the in vivo bioavailability of first transition series elements and/or removal from the body of first transition series elements and elements with similar chemical properties. These characteristics make such compounds useful in the management of diseases associated with a bodily excess of first transition series elements and elements with similar chemical properties. This invention demonstrates that such compounds inhibit mammalian, bacterial, and fungal cell replication and are therefore useful in the treatment of neoplasia, infection, inflammation, immune reponse, and in termination of pregnancy. Since these compounds are capable of descreasing the in vivo availability of tissue iron they are useful in management of free radical mediated tissue damage, and oxidation mediated tissue damage. When combined with radioisotopic or paramagnetic cations of first transition series elements, or elements with chemical properties similar to those of first transition series elements, prior to their administration, the resulting complexes are useful as diagnostic agents in nuclear medicine and magnetic resonance imaging (MRI).

  本发明涉及一类具有螯合亲和力和选择性的化合物的合成和使用，用于第一过渡系列元素。给予自由或结合化合物或生理盐的自由或结合化合物会导致体内第一过渡系列元素和具有类似化学性质的元素的生物可用性降低和/或从体内清除。这些特性使得这种化合物在管理与体内第一过渡系列元素和具有类似化学性质的元素过量相关的疾病方面非常有用。本发明表明，这种化合物抑制哺乳动物、细菌和真菌细胞复制，因此在治疗肿瘤、感染、炎症、免疫反应和终止妊娠方面非常有用。由于这些化合物能够降低组织铁的体内可用性，因此它们在管理自由基介导的组织损伤和氧化介导的组织损伤方面非常有用。当与放射性同位素或第一过渡系列元素的参数磁性阳离子或具有类似于第一过渡系列元素的化学性质的元素结合后，这些复合物在核医学和磁共振成像（MRI）的诊断剂中非常有用。
• Compounds with chelation affinity and selectivity for first transition
  申请人：Concat, Inc.

  公开号：US05874573A1

  公开（公告）日：1999-02-23

  This invention involves synthesis and use of a class of compounds with chelation affinity and selectivity for first transition series elements. Administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease in the in vivo bioavailability of first transition series elements and/or removal from the body of first transition series elements and elements with similar chemical properties. These characteristics make such compounds useful in the management of diseases associated with a bodily excess of first transition series elements and elements with similar chemical properties. This invention demonstrates that such compounds inhibit mammalian, bacterial, and fungal cell replication and are therefore useful in the treatment of neoplasia, infection, inflammation, immune response, and in termination of pregnancy. Since these compounds are capable of descreasing the in vivo availability of tissue iron they are useful in management of free radical mediated tissue damage, and oxidation mediated tissue damage. When combined with radioisotopic or paramagnetic cations of first transition series elements, or elements with chemical properties similar to those of first transition series elements, prior to their administration, the resulting complexes are useful as diagnostic agents in nuclear medicine and magnetic resonance imaging (MRI).

  本发明涉及一类具有螯合亲和力和选择性的化合物的合成和使用，用于第一过渡系列元素。自由或共轭化合物，或生理盐的自由或共轭化合物的给药，导致体内第一过渡系列元素和具有类似化学性质的元素的生物利用度降低和/或从体内清除。这些特性使得这种化合物在管理与体内过量的第一过渡系列元素和具有类似化学性质的元素相关的疾病方面非常有用。本发明证明这种化合物可以抑制哺乳动物、细菌和真菌细胞的复制，因此在治疗肿瘤、感染、炎症、免疫反应和终止妊娠方面非常有用。由于这些化合物能够降低组织中铁的生物利用度，因此它们在管理自由基介导的组织损伤和氧化介导的组织损伤方面非常有用。当与第一过渡系列元素或具有类似第一过渡系列元素化学性质的元素的放射性同位素或顺磁性阳离子结合后，在其给药之前，所得到的复合物在核医学和磁共振成像（MRI）的诊断剂方面非常有用。
• Compounds with chelation affinity selectivity for first transition
  申请人：Concat, Inc.

  公开号：US06165996A1

  公开（公告）日：2000-12-26

  This invention involves synthesis and use of a class of compounds with chelation affinity and selectivity for first transition series elements. Administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease in the in vivo bioavailability of first transition series elements and/or removal from the body of first transition series elements and elements with similar chemical properties. These characteristics make such compounds useful in the management of diseases associated with a bodily excess of first transition series elements and elements with similar chemical properties. This invention demonstrates that such compounds inhibit mammalian, bacterial, and fungal cell replication and are therefore useful in the treatment of neoplasia, infection, inflammation, immune reponse, and in termination of pregnancy. Since these compounds are capable of descreasing the in vivo availability of tissue iron they are useful in management of free radical mediated tissue damage, and oxidation mediated tissue damage. When combined with radioisotopic or paramagnetic cations of first transition series elements, or elements with chemical properties similar to those of first transition series elements, prior to their administration, the resulting complexes are useful as diagnostic agents in nuclear medicine and magnetic resonance imaging (MRI).

  这项发明涉及一类具有螯合亲和力和选择性的化合物的合成和使用，用于第一过渡系列元素。给予自由或结合化合物，或生理盐的自由或结合化合物，导致体内第一过渡系列元素和具有类似化学性质的元素的生物可用性降低和/或从体内清除。这些特性使得这种化合物在管理与身体过量第一过渡系列元素和具有类似化学性质的元素相关的疾病方面有用。这项发明证明了这些化合物抑制哺乳动物、细菌和真菌细胞复制，因此对于治疗肿瘤、感染、炎症、免疫反应和终止妊娠有用。由于这些化合物能够降低组织铁的体内可用性，因此它们在管理自由基介导的组织损伤和氧化介导的组织损伤方面有用。当与第一过渡系列元素或具有类似化学性质的元素的放射性同位素或顺磁性阳离子结合后，在其给予之前，所得到的复合物在核医学和磁共振成像（MRI）中作为诊断剂有用。